TCL Archive Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer July 26, 2002
TCL Archive In Brief: NCAB To Hear NCOG Appeal; FDA Renege On New Toxicology Protocol, Holds Up INDs April 24, 1981